Our country is experiencing shortages of COVID-19 test kits
due to supply chain disruptions that are limiting access to
critical components in commonly-used kits.
A shortage of tests results in insufficient mass-scale testing,
restricting our ability to halt the spread of the virus as it takes
more lives and disrupts our economy and way of life.
To support the fight against COVID-19, Curative has
developed a simple oral fluid swab test that is
self-collected by the patient under direct supervision and
reduces the burden on PPE while reducing exposure risk to
Our testing capabilities allow us to receive samples and
return results in about 24 hours, even as we work to process
tens of thousands of tests every day.
Our proprietary methodology employs a different supply chain
than typical test kits, reducing our reliance on an
already-strained manufacturing base.
We currently operate CLIA-certified high-complexity laboratories
in Los Angeles, CA and Washington, DC.
COVID-19 testing at scale
for your community
Fred Turner started an a16z and YC-backed diagnostics (Dx) startup that
built a CLIA lab for validating and launching an STD testing product. This
product was administered to over 10,000 patients in medical centers across
5 states. Mr. Turner was named one of the top 100 practicing scientists in
the UK by the Science Council 2013.
Dr. Isaac Turner, PhD
Dr. Turner is a co-founder of Curative Inc. with a PhD in Bioinformatics from Oxford. He develops algorithms that make sense of very noisy data from Oxford Nanopore sequencers, enabling their potential use in sepsis diagnostics. Previously at an a16z-backed startup, he helped establish a clinical lab offering novel antibiotic susceptibility tests. He led a team that scaled clinical data infrastructure, enabling them to quickly close large healthcare providers as customers in the first 9 months of launching.
Dr. Vlad Slepnev, PhD
Dr. Slepnev previously led teams that have built and launched 10
FDA-cleared diagnostic products in the infectious disease space. He led
molecular R&D at Meridian Biosciences (public Dx company), which
developed 9 FDA cleared tests + 13 CE marked tests. He is a co-founder of
Primera Dx, which raised more than $50M and sold to Qiagen.
Christopher Vanek continues his 28 years of service as one of our nation's most experienced
Special Operators and combat veterans by bringing emerging technologies to our next
generation of warfighters.
As one of the United States Army's few leaders to have commanded two brigade level
formations to include it's most elite Special Operations unit, the 75th Ranger Regiment,
Christopher brings his unique experience and expansive network to the Gothams Advisory and
Accelerator services, connecting warfighters with cutting-edge capabilities they need to
accomplish their unique missions.
After 19 years of leading the nation's most accomplished warriors on the most challenging
battlefields during our most recent conflicts, Christopher now uses that same leadership and
resilience to lead technology startups to success.
Tami Wilson-Ciranna has an extensive financial and leadership background in a variety of industries including Biotech, Manufacturing, Real Estate, Products and Energy. She previously worked as CFO of Prolacta Bioscience, Inc. a high growth biotech company. Prior to Prolacta she was CFO of CommonWealth Partners a vertically integrated real estate investment company. She has her CPA and obtained her MBA from the UCLA Anderson School of Management.
Matt Prusak previously worked as a management consultant at Bain & Company. He received his MMS while a Schwarzman scholar at Tsinghua University and studied at the Stanford Graduate School of Business for his MBA.
Dr. Lee Spraggon, PhD
Dr Lee Spraggon received his PhD in Genetics from the University of Edinburgh and the Medical Research Council in the UK. Following this, he moved to the USA, where he completed postdoctoral training at both Columbia University and Memorial Sloan Kettering Cancer Center in New York. Worked in the biotechnology sector, both in the UK and USA, leading development teams which have implemented high-throughput automation platforms for cell engineering and genomic editing.
Dr. Jeffrey Klausner, MD, MPH
Dr. Klausner is a Professor of Medicine in the Division of Infectious Diseases
and the Program in Global Health at UCLA and an independent contractor for Curative.
From 1998-2009, Dr. Klausner was a Deputy Health Officer, Director of STD
Prevention and Control Services at the San Francisco Department of Public
Health, member of the UCSF School of Medicine faculty in the Divisions of
AIDS and Infectious Diseases, and Attending Physician at San Francisco
From 2009-2011, Dr. Klausner was Branch Chief for HIV and TB at the
Centers for Disease Control in Pretoria, South Africa, helping lead the South
African PEPFAR program for care and treatment.
VP of HR
Melissa Kamita leads Human Resources at Curative, building a world class team with a close knit culture. She draws upon more than two decades of HR experience in industries ranging from non-profits to medical device manufacturing, spanning both start-ups and global companies. As the head of HR at Ariosa Diagnostics she built a hyper-growth team, growing 7x in under 3 years, and she stayed on as Director of HR at Roche Sequencing Solutions subsequent to their acquisition. Previously she was a Sr. HR Business Partner at Dionex, which was acquired by Thermo Fisher. Melissa has a BA focused in Communications from UC Santa Barbara.
VP of Field Operations
Agatha Bacelar leads Field Operations at Curative, including all drive-thru testing operations. Prior to joining Curative, she ran for U.S. Congress in San Francisco and spent five years helping scale Emerson Collective. At Emerson, she partnered with leading nonprofits, activists, artists, and policy-makers to advance education, immigration, criminal justice, and environmental reform. Agatha is also a founding member of the YC-backed non-profit, Democracy Earth, and she studied product design engineering at Stanford.